Title: Ramipril for the Treatment of COVID-19 (RAMIC)

Accession Number: NCT04366050

Link to Dataset: https://clinicaltrials.gov/study/NCT04366050

Repository: ClinicalTrials.gov

Data Type(s): Clinical Trials

Summary: In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints will be monitored at regular intervals. After 14 days, patients will undergo a laboratory assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of successful therapy will be improved survival, reductions in ICU admissions, and/or reductions in use of mechanical ventilator support.

Publication(s) associated with this dataset:

• Huang DQ, Ajmera VH, Tomaszewski C, LaFree A, Bettencourt R, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Insel PA, Leachman S, Jung J, Collier S, Richards L, Woods K, Amangurbanova M, Bhatt A, Zhang X, Penciu OM, Zarich S, Retta T, Harkins MS, Teixeira JP, Chinnock B, Utay NS, Lake JE, Loomba R. 2023. Ramipril for the treatment of COVID-19: RAMIC, a randomized, double-blind, placebo-controlled clinical trial. Adv Ther 40(11):4805-4816. doi:10.1007/s12325-023-02618-7 PMID:37615850 PMCID:PMC10709987

• Ajmera VH, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Sriram K, Insel PA, Collier S, Richards L, Loomba R. 2021. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. Contemp Clin Trials 103:doi:10.1016/j.cct.2021.106330 PMID:33631357 PMCID:PMC7899027

Project(s) associated with this dataset:

• University of California-San Diego: Administrative Core
• University of California-San Diego: The Role of Reactive Oxygen Species and the Microbiome in Toxicant Induced Liver Fibrosis